X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering May 07, 2021
Details:
Proceeds from the financing to be used in continuing to advance Gyroscope's clinical program for its investigational gene therapy, GT005, as well as our earlier stage pipeline.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GT005
Therapeutic Area: Ophthalmology Product Name: GT005
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Forbion’s Growth Opportunities Fund
Deal Size: $148.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 26, 2021
Details:
Gyroscope plans to use proceeds from the financing to advance the clinical development of GT005, the company’s lead investigational gene therapy being evaluated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
